The global optical genome mapping market was valued at USD 68.5 million in 2025. It is estimated at USD 79.4 million in 2026 and is projected to reach USD 285.6 million by 2036, at a CAGR of 13.7% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering structural variant detection, the replacement of conventional cytogenetics, clinical guidelines and evidence, reimbursement and regulation, electronic genome mapping, pricing and cost per sample, the supplier landscape, and future growth opportunities.
The market covers the instruments, consumables, software, and services used to label, stretch, and image very long DNA molecules so that structural variants can be found across the whole genome. Products in scope include nanochannel systems that straighten and photograph DNA strands several hundred kilobases in length, flowcells and chips, kits for extracting and labeling long DNA, software for analysis and reporting, and testing services for research and clinical customers, including laboratory-developed tests for blood cancers and constitutional disorders. Electronic genome mapping, which reads labeled long DNA molecules electrically instead of optically, is also included. Karyotyping, FISH, chromosomal microarray, sequencing products and services, and general DNA extraction products not designed for ultra-high-molecular-weight DNA are excluded.
Recommendations written by 19 experts of the International Consortium for Optical Genome Mapping (ICOGM) and published in the American Journal of Hematology in May 2025 position OGM as a first-line test, in place of karyotyping and FISH, for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, B- and T-lineage acute lymphoblastic leukemia, and childhood leukemias whenever high-resolution genome-wide detection is required. According to the Centers for Medicare & Medicaid Services (CMS), its final 2026 laboratory fee schedule raised the payment rate for CPT code 81195, which covers OGM in hematologic malignancies, by 47% to USD 1,853.22 from January 1, 2026.
OGM systems require significant capital spending, and the method needs ultra-high-molecular-weight DNA from fresh or frozen samples, which limits use with formalin-fixed, paraffin-embedded tissue and degraded material, particularly in solid tumors. Most systems are sold for research use only, so clinical testing relies on laboratory-developed tests that each laboratory must validate, and the small number of cleared clinical products can slow uptake where rules are stricter. The field also faces competition from long-read sequencing, mapped-read methods on installed short-read instruments, and electronic genome mapping, and it depends on a few specialized providers with limited financial resources, which can make customers cautious about long-term platform commitments.
Expansion into constitutional disorders, prenatal testing, and reproductive health is a significant opportunity, as OGM detects balanced rearrangements, repeat expansions, and complex variants linked to infertility, pregnancy loss, developmental delay, and rare disease, and CPT code 81354 provides a payment route for constitutional testing. Genome integrity testing of edited cells, engineered cell lines, and cell banks for cell and gene therapy, higher-throughput systems and AI analysis software such as Bionano's Stratys system and VIA software, and solid tumor and multiple myeloma uses offer further openings. Key trends include the move from research to clinical use, the inclusion of OGM in testing algorithms, the arrival of electronic genome mapping, and combined use of mapping and sequencing.
By offering, the optical genome mapping market is segmented into instruments, consumables (flowcells & chips and DNA isolation & labeling kits), software, and services (clinical testing services and research services). Consumables are expected to hold the largest share in 2026, because every sample needs flowcells and DNA isolation and labeling kits, Bionano's installed base reached 387 systems at the end of 2025 with 30,171 flowcells sold that year, and growing clinical use is raising run volumes at existing sites. Services are set to record the highest CAGR, as more clinical laboratories launch OGM-based laboratory-developed tests, the higher 2026 payment rate for CPT code 81195 improves test economics, and CPT code 81354 supports constitutional testing. Software is expected to grow strongly as AI tools simplify interpretation, while instruments should recover as higher-throughput systems arrive and new clinical sites open.
By application, the optical genome mapping market is segmented into hematologic malignancies, solid tumors, constitutional genetic disorders, reproductive health & prenatal testing, cell & gene therapy and cell line characterization, and genome assembly & other research applications. Hematologic malignancies are expected to account for the largest share in 2026, reflecting established use in leukemia and myelodysplastic syndrome testing, the ICOGM first-line recommendations, and dedicated Category I CPT coding with an improved 2026 payment rate. Reproductive health & prenatal testing is set to grow at the highest CAGR, driven by fast-growing evidence, with 13 studies covering 730 subjects published in 2026 by the second quarter, and by OGM's ability to find balanced rearrangements tied to infertility and pregnancy loss. Constitutional genetic disorders hold a significant share, while cell and gene therapy use is rising as developers adopt genome integrity testing.
By end user, the optical genome mapping market is segmented into clinical & cytogenetic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other end users. Academic & research institutes are expected to hold the largest share in 2026, as universities and genome centers own much of the installed base and run OGM for rearrangement studies, genome assembly, and translational projects. Clinical & cytogenetic laboratories are set to record the highest CAGR, driven by the replacement of traditional cytogenetic methods, better reimbursement, and expert recommendations; Bionano reported that clinical adoption was the main reason for its 31% consumables revenue growth in the second quarter of 2026. Pharmaceutical and biotechnology companies are a growing user group for cell and gene therapy quality control, often through outsourced testing.
In 2026, North America is expected to lead the global optical genome mapping market, owing to its many hospital cytogenetics laboratories, university medical centers, and research institutes, the presence of Bionano Genomics and Nabsys, and Category I CPT codes for OGM. In the U.S., dedicated CPT codes, the CLIA route for laboratory-developed tests, and a wide base of reference laboratories help new OGM tests enter clinical practice sooner than in most other countries, while Johns Hopkins, MD Anderson, and Columbia University are producing supporting evidence. Canada adds demand through provincial genetics programs and academic hematology centers. Europe holds a significant share, led by Germany, the U.K., France, Italy, the Netherlands, and Spain, where large hematology and clinical genetics networks are active in OGM research, although stricter EU IVDR rules for in-house and research-use-only products are likely to shape the pace of clinical uptake.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, supported by big patient populations, growing national genomic medicine efforts, and rising spending on cancer and rare disease testing. China is expected to hold the largest share in the region, where Bionano's OEM partner Beijing Genome Precision Technology has secured NMPA Class I registrations for its DNA labeling kit and its kit for isolating DNA from bone marrow aspirate, both for diagnostic use in blood cancers. Japanese research and clinical genetics groups are expected to adopt genome mapping more widely, helped by Hitachi High-Tech, which presented electronic genome mapping data with Nabsys at the Japanese Society of Human Genetics meeting in December 2025, while South Korea, Australia, and India contribute through clinical genomics and academic programs. Latin America and the Middle East & Africa hold smaller shares, supported by academic research, developing clinical genetics services, and national genomics initiatives.
The optical genome mapping market is highly concentrated, with Bionano Genomics as the leading platform provider, alongside the electronic genome mapping developer Nabsys and its industrial partner Hitachi High-Tech, regional OEM and distribution partners, and laboratories offering OGM-based testing. Suppliers compete on structural variant detection, throughput, cost per sample, sample preparation needs, ease of analysis, clinical evidence, and reimbursement support. Leading players are investing in higher-throughput systems, AI software, clinical studies, reimbursement work, and partnerships. Recent activity includes the higher CMS payment rate for CPT code 81195 secured after a request by Bionano Laboratories, new OhmX installations at Columbia University announced by Nabsys in May 2026 under Hitachi High-Tech America's RAMP UP program, and the Chinese reagent registrations obtained by Beijing Genome Precision Technology.
Key companies profiled in the report include Bionano Genomics, Inc. (U.S.), Nabsys 2.0, LLC (U.S.), Hitachi High-Tech Corporation (Japan), and Beijing Genome Precision Technology Co., Ltd. (China).
The market covers the instruments, consumables, software, and services used to label, stretch, and image very long DNA molecules so that structural variants can be found across the whole genome. Products in scope include nanochannel systems that straighten and photograph DNA strands several hundred kilobases in length, flowcells and chips, kits for extracting and labeling long DNA, software for analysis and reporting, and testing services for research and clinical customers, including laboratory-developed tests for blood cancers and constitutional disorders. Electronic genome mapping, which reads labeled long DNA molecules electrically instead of optically, is also included. Karyotyping, FISH, chromosomal microarray, sequencing products and services, and general DNA extraction products not designed for ultra-high-molecular-weight DNA are excluded.
Recommendations written by 19 experts of the International Consortium for Optical Genome Mapping (ICOGM) and published in the American Journal of Hematology in May 2025 position OGM as a first-line test, in place of karyotyping and FISH, for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms, B- and T-lineage acute lymphoblastic leukemia, and childhood leukemias whenever high-resolution genome-wide detection is required. According to the Centers for Medicare & Medicaid Services (CMS), its final 2026 laboratory fee schedule raised the payment rate for CPT code 81195, which covers OGM in hematologic malignancies, by 47% to USD 1,853.22 from January 1, 2026.
Market Dynamics
Whole-genome structural variant detection in a single assay is a major driver of the optical genome mapping market, since large-scale DNA rearrangements are a major source of inherited disease and a key factor in cancer, and many are missed by conventional cytogenetics or short-read sequencing. Because each imaged molecule is so long, OGM can pick up balanced translocations, inversions, insertions, deletions, and copy number gains or losses and can resolve complex rearrangements; in a T-cell acute lymphoblastic leukemia study reported by Bionano in 2026, OGM found abnormalities in 97.8% of cases against 55% for karyotyping. Laboratories are also consolidating karyotype, FISH, and microarray work into one higher-resolution test, which cuts turnaround time and workload. Better reimbursement, with Category I CPT codes 81195 and 81354, and a fast-growing body of evidence, including 136 peer-reviewed publications reported by Bionano in the fourth quarter of 2025, support further adoption.OGM systems require significant capital spending, and the method needs ultra-high-molecular-weight DNA from fresh or frozen samples, which limits use with formalin-fixed, paraffin-embedded tissue and degraded material, particularly in solid tumors. Most systems are sold for research use only, so clinical testing relies on laboratory-developed tests that each laboratory must validate, and the small number of cleared clinical products can slow uptake where rules are stricter. The field also faces competition from long-read sequencing, mapped-read methods on installed short-read instruments, and electronic genome mapping, and it depends on a few specialized providers with limited financial resources, which can make customers cautious about long-term platform commitments.
Expansion into constitutional disorders, prenatal testing, and reproductive health is a significant opportunity, as OGM detects balanced rearrangements, repeat expansions, and complex variants linked to infertility, pregnancy loss, developmental delay, and rare disease, and CPT code 81354 provides a payment route for constitutional testing. Genome integrity testing of edited cells, engineered cell lines, and cell banks for cell and gene therapy, higher-throughput systems and AI analysis software such as Bionano's Stratys system and VIA software, and solid tumor and multiple myeloma uses offer further openings. Key trends include the move from research to clinical use, the inclusion of OGM in testing algorithms, the arrival of electronic genome mapping, and combined use of mapping and sequencing.
Segment Analysis
The report analyzes the market by offering, application, end user, and geography, helping stakeholders identify the most attractive areas for product development, clinical expansion, partnering, and investment.By offering, the optical genome mapping market is segmented into instruments, consumables (flowcells & chips and DNA isolation & labeling kits), software, and services (clinical testing services and research services). Consumables are expected to hold the largest share in 2026, because every sample needs flowcells and DNA isolation and labeling kits, Bionano's installed base reached 387 systems at the end of 2025 with 30,171 flowcells sold that year, and growing clinical use is raising run volumes at existing sites. Services are set to record the highest CAGR, as more clinical laboratories launch OGM-based laboratory-developed tests, the higher 2026 payment rate for CPT code 81195 improves test economics, and CPT code 81354 supports constitutional testing. Software is expected to grow strongly as AI tools simplify interpretation, while instruments should recover as higher-throughput systems arrive and new clinical sites open.
By application, the optical genome mapping market is segmented into hematologic malignancies, solid tumors, constitutional genetic disorders, reproductive health & prenatal testing, cell & gene therapy and cell line characterization, and genome assembly & other research applications. Hematologic malignancies are expected to account for the largest share in 2026, reflecting established use in leukemia and myelodysplastic syndrome testing, the ICOGM first-line recommendations, and dedicated Category I CPT coding with an improved 2026 payment rate. Reproductive health & prenatal testing is set to grow at the highest CAGR, driven by fast-growing evidence, with 13 studies covering 730 subjects published in 2026 by the second quarter, and by OGM's ability to find balanced rearrangements tied to infertility and pregnancy loss. Constitutional genetic disorders hold a significant share, while cell and gene therapy use is rising as developers adopt genome integrity testing.
By end user, the optical genome mapping market is segmented into clinical & cytogenetic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and other end users. Academic & research institutes are expected to hold the largest share in 2026, as universities and genome centers own much of the installed base and run OGM for rearrangement studies, genome assembly, and translational projects. Clinical & cytogenetic laboratories are set to record the highest CAGR, driven by the replacement of traditional cytogenetic methods, better reimbursement, and expert recommendations; Bionano reported that clinical adoption was the main reason for its 31% consumables revenue growth in the second quarter of 2026. Pharmaceutical and biotechnology companies are a growing user group for cell and gene therapy quality control, often through outsourced testing.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 18 countries and four rest-of-region groups. The regional analysis of the optical genome mapping market considers clinical cytogenetics capacity, reimbursement and coding, regulatory pathways such as EU IVDR and China NMPA rules, research activity, and the presence of platform providers and partners.In 2026, North America is expected to lead the global optical genome mapping market, owing to its many hospital cytogenetics laboratories, university medical centers, and research institutes, the presence of Bionano Genomics and Nabsys, and Category I CPT codes for OGM. In the U.S., dedicated CPT codes, the CLIA route for laboratory-developed tests, and a wide base of reference laboratories help new OGM tests enter clinical practice sooner than in most other countries, while Johns Hopkins, MD Anderson, and Columbia University are producing supporting evidence. Canada adds demand through provincial genetics programs and academic hematology centers. Europe holds a significant share, led by Germany, the U.K., France, Italy, the Netherlands, and Spain, where large hematology and clinical genetics networks are active in OGM research, although stricter EU IVDR rules for in-house and research-use-only products are likely to shape the pace of clinical uptake.
Asia-Pacific is projected to grow at the highest CAGR during the forecast period, supported by big patient populations, growing national genomic medicine efforts, and rising spending on cancer and rare disease testing. China is expected to hold the largest share in the region, where Bionano's OEM partner Beijing Genome Precision Technology has secured NMPA Class I registrations for its DNA labeling kit and its kit for isolating DNA from bone marrow aspirate, both for diagnostic use in blood cancers. Japanese research and clinical genetics groups are expected to adopt genome mapping more widely, helped by Hitachi High-Tech, which presented electronic genome mapping data with Nabsys at the Japanese Society of Human Genetics meeting in December 2025, while South Korea, Australia, and India contribute through clinical genomics and academic programs. Latin America and the Middle East & Africa hold smaller shares, supported by academic research, developing clinical genetics services, and national genomics initiatives.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and market share/rank analysis by key player for 2025. Company profiles include business overviews, financial performance, genome mapping and product portfolios, strategic developments, and SWOT analyses.The optical genome mapping market is highly concentrated, with Bionano Genomics as the leading platform provider, alongside the electronic genome mapping developer Nabsys and its industrial partner Hitachi High-Tech, regional OEM and distribution partners, and laboratories offering OGM-based testing. Suppliers compete on structural variant detection, throughput, cost per sample, sample preparation needs, ease of analysis, clinical evidence, and reimbursement support. Leading players are investing in higher-throughput systems, AI software, clinical studies, reimbursement work, and partnerships. Recent activity includes the higher CMS payment rate for CPT code 81195 secured after a request by Bionano Laboratories, new OhmX installations at Columbia University announced by Nabsys in May 2026 under Hitachi High-Tech America's RAMP UP program, and the Chinese reagent registrations obtained by Beijing Genome Precision Technology.
Key companies profiled in the report include Bionano Genomics, Inc. (U.S.), Nabsys 2.0, LLC (U.S.), Hitachi High-Tech Corporation (Japan), and Beijing Genome Precision Technology Co., Ltd. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global optical genome mapping market.
- Explains how expert recommendations, reimbursement changes, and the replacement of karyotyping, FISH, and microarray are driving clinical adoption.
- Assesses the impact of capital costs, sample requirements, research-use-only status, and competition from sequencing-based methods.
- Identifies high-growth opportunities across offering, application, end user, and region.
- Tracks electronic genome mapping, higher-throughput systems, AI analysis software, and new prenatal and cell and gene therapy uses.
- Benchmarks leading companies by platform performance, installed base, clinical evidence, partnerships, and regulatory progress.
- Supports product planning, test menu development, partnering, and market entry decisions for platform providers, clinical laboratories, cell and gene therapy developers, and investors.
Key Questions Answered
- How big is the global optical genome mapping market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are the ICOGM recommendations and CMS payment changes affecting clinical use of OGM?
- Which offering, application, and end-user segments will grow the fastest?
- How quickly will OGM be adopted in constitutional, prenatal, and reproductive health testing?
- How does OGM compare with karyotyping, FISH, microarray, and long-read sequencing?
- What role will electronic genome mapping play in the competitive landscape?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and what strategies are they using to expand clinical adoption?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Optical Genome Mapping Market, by Offering
6. Optical Genome Mapping Market, by Application
7. Optical Genome Mapping Market, by End User
8. Optical Genome Mapping Market, by Geography
9. Competitive Landscape
10. Company Profiles
11. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Bionano Genomics, Inc.
- Nabsys 2.0, LLC
- Hitachi High-Tech Corporation
- Beijing Genome Precision Technology Co., Ltd.
